Sunday, July 27, 2025 8:24:56 PM
Thanks Slave,
I wonder if the FDA could tell NWBO that they'd consider the UK filing to be a BLA under Orbis, but because of Orbis it shouldn't be revealed.
I'm not saying this has happened, but if this was done under Orbis, the trial could be taking so long as the company, or its contractors, could very well be answering the questions from all four of the regulators participating in the Phase 3 trial.
If any, or all of this were done under Orbis, but if the regulators couldn't reach a common agreement, I don't know that we'd ever be told. I suspect the UK would announce approval and over a reasonably short period of time others could concur with the UK decision and rapidly approve our vaccine.
We all need to remember how long it took during the trial halt for all the regulators to agree on a path forward. I believe an agreement of all four of them under Orbis would be much the same.
Gary
I wonder if the FDA could tell NWBO that they'd consider the UK filing to be a BLA under Orbis, but because of Orbis it shouldn't be revealed.
I'm not saying this has happened, but if this was done under Orbis, the trial could be taking so long as the company, or its contractors, could very well be answering the questions from all four of the regulators participating in the Phase 3 trial.
If any, or all of this were done under Orbis, but if the regulators couldn't reach a common agreement, I don't know that we'd ever be told. I suspect the UK would announce approval and over a reasonably short period of time others could concur with the UK decision and rapidly approve our vaccine.
We all need to remember how long it took during the trial halt for all the regulators to agree on a path forward. I believe an agreement of all four of them under Orbis would be much the same.
Gary
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
